These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36426859)

  • 1. Dysregulation of HNF1B/Clusterin axis enhances disease progression in a highly aggressive subset of pancreatic cancer patients.
    Yang S; Tang W; Azizian A; Gaedcke J; Ströbel P; Wang L; Cawley H; Ohara Y; Valenzuela P; Zhang L; Lal T; Sinha S; Rupin E; Hanna N; Ghadimi BM; Hussain SP
    Carcinogenesis; 2022 Dec; 43(12):1198-1210. PubMed ID: 36426859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
    Wang X; Xie J; Lu X; Li H; Wen C; Huo Z; Xie J; Shi M; Tang X; Chen H; Peng C; Fang Y; Deng X; Shen B
    Cancer Lett; 2017 Jul; 399():1-9. PubMed ID: 28428074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.
    Yang S; He P; Wang J; Schetter A; Tang W; Funamizu N; Yanaga K; Uwagawa T; Satoskar AR; Gaedcke J; Bernhardt M; Ghadimi BM; Gaida MM; Bergmann F; Werner J; Ried T; Hanna N; Alexander HR; Hussain SP
    Cancer Res; 2016 Jul; 76(13):3838-50. PubMed ID: 27197190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma.
    Funamizu N; Hu C; Lacy C; Schetter A; Zhang G; He P; Gaedcke J; Ghadimi MB; Ried T; Yfantis HG; Lee DH; Subleski J; Chan T; Weiss JM; Back TC; Yanaga K; Hanna N; Alexander HR; Maitra A; Hussain SP
    Int J Cancer; 2013 Feb; 132(4):785-94. PubMed ID: 22821831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
    Okada Y; Takahashi N; Takayama T; Goel A
    Carcinogenesis; 2021 Apr; 42(4):546-556. PubMed ID: 33624791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human pancreatic cancer patients with Epithelial-to-Mesenchymal Transition and an aggressive phenotype show a disturbed balance in Protein Phosphatase Type 2A expression and functionality.
    van Pelt J; Meeusen B; Derua R; Guffens L; Van Cutsem E; Janssens V; Verslype C
    J Transl Med; 2023 May; 21(1):317. PubMed ID: 37170215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression.
    Wang WY; Hsu CC; Wang TY; Li CR; Hou YC; Chu JM; Lee CT; Liu MS; Su JJ; Jian KY; Huang SS; Jiang SS; Shan YS; Lin PW; Shen YY; Lee MT; Chan TS; Chang CC; Chen CH; Chang IS; Lee YL; Chen LT; Tsai KK
    Gastroenterology; 2013 Nov; 145(5):1110-20. PubMed ID: 23896173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymal-to-epithelial transition through modulating the ERK/Slug pathway.
    Chou TY; Chen WC; Lee AC; Hung SM; Shih NY; Chen MY
    Cell Signal; 2009 May; 21(5):704-11. PubMed ID: 19166932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of clusterin expression in the refractory response of pancreatic cancer cells to a MEK inhibitor.
    Amada K; Hijiya N; Ikarimoto S; Yanagihara K; Hanada T; Hidano S; Kurogi S; Tsukamoto Y; Nakada C; Kinoshita K; Hirashita Y; Uchida T; Shin T; Yada K; Hirashita T; Kobayashi T; Murakami K; Inomata M; Shirao K; Aoki M; Takekawa M; Moriyama M
    Cancer Sci; 2023 May; 114(5):2189-2202. PubMed ID: 36694355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Clusterin Represses Proliferation by Inducing Cellular Senescence in Pancreatic Cancer.
    Mitsufuji S; Iwagami Y; Kobayashi S; Sasaki K; Yamada D; Tomimaru Y; Akita H; Asaoka T; Noda T; Gotoh K; Takahashi H; Tanemura M; Doki Y; Eguchi H
    Ann Surg Oncol; 2022 Aug; 29(8):4937-4946. PubMed ID: 35397747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.
    Zhang G; Schetter A; He P; Funamizu N; Gaedcke J; Ghadimi BM; Ried T; Hassan R; Yfantis HG; Lee DH; Lacy C; Maitra A; Hanna N; Alexander HR; Hussain SP
    PLoS One; 2012; 7(2):e31507. PubMed ID: 22363658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
    Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
    J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
    Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
    Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
    Gordon ER; Wright CA; James M; Cooper SJ
    BMC Cancer; 2023 Jun; 23(1):524. PubMed ID: 37291514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pooled CRISPR screening in pancreatic cancer cells implicates co-repressor complexes as a cause of multiple drug resistance via regulation of epithelial-to-mesenchymal transition.
    Ramaker RC; Hardigan AA; Gordon ER; Wright CA; Myers RM; Cooper SJ
    BMC Cancer; 2021 May; 21(1):632. PubMed ID: 34049503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.
    Li Z; Zhao X; Zhou Y; Liu Y; Zhou Q; Ye H; Wang Y; Zeng J; Song Y; Gao W; Zheng S; Zhuang B; Chen H; Li W; Li H; Li H; Fu Z; Chen R
    J Transl Med; 2015 Mar; 13():84. PubMed ID: 25889214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miRNA-193b-5p Suppresses Pancreatic Cancer Cell Proliferation, Invasion, Epithelial Mesenchymal Transition, and Tumor Growth by Inhibiting eEF2K.
    Gurbuz N; Kahraman N; Sonmez HE; Mokhlis HA; Kosar PA; Ozpolat B
    Anticancer Agents Med Chem; 2022; 22(14):2607-2618. PubMed ID: 35718922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
    Zhu H; Gao W; Li X; Yu L; Luo D; Liu Y; Yu X
    Pancreatology; 2021 Apr; 21(3):589-598. PubMed ID: 33579599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma.
    Janky R; Binda MM; Allemeersch J; Van den Broeck A; Govaere O; Swinnen JV; Roskams T; Aerts S; Topal B
    BMC Cancer; 2016 Aug; 16():632. PubMed ID: 27520560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nicotine-induced positive feedback loop between HIF1A and YAP1 contributes to epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma.
    Ben Q; An W; Sun Y; Qian A; Liu J; Zou D; Yuan Y
    J Exp Clin Cancer Res; 2020 Sep; 39(1):181. PubMed ID: 32894161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.